CGEN - Compugen

-

$undefined

N/A

(N/A)

Compugen NASDAQ:CGEN Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.

Location: | Website: www.cgen.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

60.54M

Cash

92.0M

Avg Qtr Burn

N/A

Short % of Float

1.83%

Insider Ownership

5.38%

Institutional Own.

14.90%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rilvegostomig (PD-1/TIGIT) Details
Cancer, Biliary Tract Cancer

Phase 3

Data readout

Rilvegostomig (PD-1/TIGIT) Details
Cancer, Biliary Tract Cancer

Phase 2b

Data readout

Rilvegostomig (PD-1/TIGIT) Details
Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer

Phase 2

Data readout

COM701 + Opdivo (nivolumab) +/- BMS-986207 Details
Endometrial cancer, Cancer, Ovarian cancer

Phase 1/2

Update

COM701 + Opdivo (nivolumab) Details
Cancer, Solid tumor/s, Metastatic breast cancer

Phase 1b

Update

COM902 (TIGIT) Details
Cancer, Advanced malignancies

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Platinum-resistant ovarian cancer

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Colorectal cancer

Phase 1

Update

COM503 Details
Cancer, Solid tumor/s

Phase 1

Initiation

COM701 (PVRIG) Details
Ovarian cancer, Colorectal cancer , Non-small cell lung carcinoma, Breast cancer, Endometrial cancer, Cancer

Failed

Discontinued